Ross
Well-known member
Obviously, the dosing stupidity is at an all time high.
MedWatch - The FDA Safety Information and Adverse Event Reporting Program
FDA approved updated labeling to include pharmacogenomics information to
the CLINICAL PHARMACOLOGY, PRECAUTIONS, and DOSAGE AND ADMINISTRATION
sections of the prescribing information for the widely used
blood-thinning drug, Coumadin. This new information explains that
people's genetic makeup may influence how they respond to the drug.
Specifically, people with variations in two genes may need lower
warfarin doses than people without these genetic variations. The two
genes are called CYP2C9 and VKORC1. The CYP2C9 gene is involved in the
breakdown (metabolism) of warfarin and the VKORC1 gene helps regulate
the ability of warfarin to prevent blood from clotting.
The dosage and administration of warfarin must be individualized for
each patient according to the particular patient's prothrombin time (PT)
/ International Normalized Ratio (INR) response to the drug. The
specific dose recommendations are described in the warfarin product
labeling, along with the new information regarding the impact of genetic
information upon the initial dose and the response to warfarin. Ongoing
warfarin therapy should be guided by continued INR monitoring.
Read the complete MedWatch 2007 Safety summary, including a link to the
FDA Drug Information Page, at:
http://www.fda.gov/medwatch/safety/2007/safety07.htm#Warfarin
MedWatch - The FDA Safety Information and Adverse Event Reporting Program
FDA approved updated labeling to include pharmacogenomics information to
the CLINICAL PHARMACOLOGY, PRECAUTIONS, and DOSAGE AND ADMINISTRATION
sections of the prescribing information for the widely used
blood-thinning drug, Coumadin. This new information explains that
people's genetic makeup may influence how they respond to the drug.
Specifically, people with variations in two genes may need lower
warfarin doses than people without these genetic variations. The two
genes are called CYP2C9 and VKORC1. The CYP2C9 gene is involved in the
breakdown (metabolism) of warfarin and the VKORC1 gene helps regulate
the ability of warfarin to prevent blood from clotting.
The dosage and administration of warfarin must be individualized for
each patient according to the particular patient's prothrombin time (PT)
/ International Normalized Ratio (INR) response to the drug. The
specific dose recommendations are described in the warfarin product
labeling, along with the new information regarding the impact of genetic
information upon the initial dose and the response to warfarin. Ongoing
warfarin therapy should be guided by continued INR monitoring.
Read the complete MedWatch 2007 Safety summary, including a link to the
FDA Drug Information Page, at:
http://www.fda.gov/medwatch/safety/2007/safety07.htm#Warfarin